{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,13]],"date-time":"2026-10-13T13:58:12Z","timestamp":1791899892010,"version":"4.3.4"},"reference-count":40,"publisher":"Elsevier BV","issue":"5","license":[{"start":{"date-parts":[[2017,5,1]],"date-time":"2017-05-01T00:00:00Z","timestamp":1493596800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2017,5,1]],"date-time":"2017-05-01T00:00:00Z","timestamp":1493596800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"}],"funder":[{"DOI":"10.13039\/100006108","name":"National Center for Advancing Translational Sciences","doi-asserted-by":"publisher","award":["UL1 TR000135"],"award-info":[{"award-number":["UL1 TR000135"]}],"id":[{"id":"10.13039\/100006108","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["ajkd.org","clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["American Journal of Kidney Diseases"],"published-print":{"date-parts":[[2017,5]]},"DOI":"10.1053\/j.ajkd.2016.11.016","type":"journal-article","created":{"date-parts":[[2017,1,25]],"date-time":"2017-01-25T09:00:20Z","timestamp":1485334820000},"page":"658-666","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":80,"title":["Cystatin C\u2013Guided Vancomycin Dosing in Critically Ill Patients: A\u00a0Quality Improvement Project"],"prefix":"10.1053","volume":"69","author":[{"given":"Erin","family":"Frazee","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Andrew D.","family":"Rule","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"John C.","family":"Lieske","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kianoush B.","family":"Kashani","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jason N.","family":"Barreto","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Abinash","family":"Virk","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Philip J.","family":"Kuper","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ross A.","family":"Dierkhising","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Nelson","family":"Leung","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1053\/j.ajkd.2016.11.016_bib1","unstructured":"Vancomycin full prescribing information. Lake Forest, IL: Hospira, Inc; 2011:1-8."},{"key":"10.1053\/j.ajkd.2016.11.016_bib2","doi-asserted-by":"crossref","first-page":"149","DOI":"10.1016\/j.clinthera.2011.12.013","article-title":"Incidence of nephrotoxicity and association with vancomycin use in intensive care unit patients with pneumonia: retrospective analysis of the IMPACT-HAP Database","volume":"34","author":"Cano","year":"2012","journal-title":"Clin Ther"},{"key":"10.1053\/j.ajkd.2016.11.016_bib3","doi-asserted-by":"crossref","first-page":"195","DOI":"10.1002\/j.1875-9114.2011.01017.x","article-title":"Effects of targeting higher vancomycin trough levels on clinical outcomes and costs in a matched patient cohort","volume":"32","author":"Kullar","year":"2012","journal-title":"Pharmacotherapy"},{"key":"10.1053\/j.ajkd.2016.11.016_bib4","doi-asserted-by":"crossref","first-page":"448","DOI":"10.1086\/381093","article-title":"Clinical features associated with bacteremia due to heterogeneous vancomycin-intermediate Staphylococcus aureus","volume":"38","author":"Charles","year":"2004","journal-title":"Clin Infect Dis"},{"key":"10.1053\/j.ajkd.2016.11.016_bib5","doi-asserted-by":"crossref","first-page":"483","DOI":"10.1128\/AAC.01088-08","article-title":"Vancomycin ototoxicity: a reevaluation in an era of increasing doses","volume":"53","author":"Forouzesh","year":"2009","journal-title":"Antimicrob Agents Chemother"},{"key":"10.1053\/j.ajkd.2016.11.016_bib6","doi-asserted-by":"crossref","first-page":"R110","DOI":"10.1186\/cc13899","article-title":"Serum cystatin C predicts vancomycin trough levels better than serum creatinine in hospitalized patients: a cohort study","volume":"18","author":"Frazee","year":"2014","journal-title":"Crit Care"},{"key":"10.1053\/j.ajkd.2016.11.016_bib7","doi-asserted-by":"crossref","first-page":"1589","DOI":"10.1097\/01.CCM.0000217961.75225.E9","article-title":"Duration of hypotension before initiation of effective antimicrobial therapy is the critical determinant of survival in human septic shock","volume":"34","author":"Kumar","year":"2006","journal-title":"Crit Care Med"},{"key":"10.1053\/j.ajkd.2016.11.016_bib8","doi-asserted-by":"crossref","first-page":"580","DOI":"10.1097\/CCM.0b013e31827e83af","article-title":"Surviving sepsis campaign: international guidelines for management of severe sepsis and septic shock: 2012","volume":"41","author":"Dellinger","year":"2013","journal-title":"Crit Care Med"},{"key":"10.1053\/j.ajkd.2016.11.016_bib9","doi-asserted-by":"crossref","first-page":"262","DOI":"10.11613\/BM.2015.027","article-title":"Cost-effectiveness analysis of acute kidney injury biomarkers in pediatric cardiac surgery","volume":"25","author":"Petrovic","year":"2015","journal-title":"Biochem Med (Zagreb)"},{"key":"10.1053\/j.ajkd.2016.11.016_bib10","doi-asserted-by":"crossref","first-page":"498","DOI":"10.1016\/j.clinbiochem.2008.01.022","article-title":"Cystatin C could be a replacement to serum creatinine for diagnosing and monitoring kidney function in children","volume":"41","author":"Narvaez-Sanchez","year":"2008","journal-title":"Clin Biochem"},{"key":"10.1053\/j.ajkd.2016.11.016_bib11","doi-asserted-by":"crossref","first-page":"1466","DOI":"10.1056\/NEJM199711133372012","article-title":"The threat to medical-records research","volume":"337","author":"Melton","year":"1997","journal-title":"N\u00a0Engl J Med"},{"key":"10.1053\/j.ajkd.2016.11.016_bib12","series-title":"Mayo Clinic Antimicrobial Therapy: Quick Guide","author":"Wilson","year":"2012"},{"key":"10.1053\/j.ajkd.2016.11.016_bib13","doi-asserted-by":"crossref","first-page":"325","DOI":"10.1086\/600877","article-title":"Vancomycin therapeutic guidelines: a summary of consensus recommendations from the Infectious Diseases Society of America, the American Society of Health-System Pharmacists, and the Society of Infectious Diseases Pharmacists","volume":"49","author":"Rybak","year":"2009","journal-title":"Clin Infect Dis"},{"key":"10.1053\/j.ajkd.2016.11.016_bib14","doi-asserted-by":"crossref","first-page":"604","DOI":"10.1002\/j.1875-9114.2012.01098.x","article-title":"Impact of various body weights and serum creatinine concentrations on the bias and accuracy of the Cockcroft-Gault equation","volume":"32","author":"Winter","year":"2012","journal-title":"Pharmacotherapy"},{"key":"10.1053\/j.ajkd.2016.11.016_bib15","doi-asserted-by":"crossref","first-page":"31","DOI":"10.1159\/000180580","article-title":"Prediction of creatinine clearance from serum creatinine","volume":"16","author":"Cockcroft","year":"1976","journal-title":"Nephron"},{"key":"10.1053\/j.ajkd.2016.11.016_bib16","doi-asserted-by":"crossref","first-page":"285","DOI":"10.1093\/cid\/cir034","article-title":"Clinical practice guidelines by the Infectious Diseases Society of America for the treatment of methicillin-resistant Staphylococcus aureus infections in adults and children: executive summary","volume":"52","author":"Liu","year":"2011","journal-title":"Clin Infect Dis"},{"key":"10.1053\/j.ajkd.2016.11.016_bib17","series-title":"The Six Sigma Handbook: A Complete Guide for Green Belts, Black Belts, and Managers at All Levels","author":"Pyzdek","year":"2010"},{"key":"10.1053\/j.ajkd.2016.11.016_bib18","doi-asserted-by":"crossref","first-page":"863","DOI":"10.1001\/archinte.1916.00080130010002","article-title":"Clinical calorimetry: tenth paper. A formula to estimate the approximate surface area if height and weight be known","volume":"17","author":"Du Bois","year":"1916","journal-title":"Arch Intern Med"},{"key":"10.1053\/j.ajkd.2016.11.016_bib19","doi-asserted-by":"crossref","first-page":"20","DOI":"10.1056\/NEJMoa1114248","article-title":"Estimating glomerular filtration rate from serum creatinine and cystatin C [erratum in N Engl J Med. 2012;367(7):681]","volume":"367","author":"Inker","year":"2012","journal-title":"N\u00a0Engl J Med"},{"key":"10.1053\/j.ajkd.2016.11.016_bib20","doi-asserted-by":"crossref","first-page":"159","DOI":"10.1086\/510393","article-title":"Infectious Diseases Society of America and the Society for Healthcare Epidemiology of America guidelines for developing an institutional program to enhance antimicrobial stewardship","volume":"44","author":"Dellit","year":"2007","journal-title":"Clin Infect Dis"},{"key":"10.1053\/j.ajkd.2016.11.016_bib21","first-page":"1","article-title":"KDIGO clinical practice guideline for acute kidney injury","volume":"2","author":"Kellum","year":"2012","journal-title":"Kidney Int Suppl"},{"key":"10.1053\/j.ajkd.2016.11.016_bib22","doi-asserted-by":"crossref","first-page":"621","DOI":"10.1093\/cid\/cir895","article-title":"Linezolid in methicillin-resistant Staphylococcus aureus nosocomial pneumonia: a randomized, controlled study","volume":"54","author":"Wunderink","year":"2012","journal-title":"Clin Infect Dis"},{"key":"10.1053\/j.ajkd.2016.11.016_bib23","doi-asserted-by":"crossref","first-page":"377","DOI":"10.1016\/j.jbi.2008.08.010","article-title":"Research Electronic Data Capture (REDCap)\u2013a metadata-driven methodology and workflow process for providing translational research informatics support","volume":"42","author":"Harris","year":"2009","journal-title":"J\u00a0Biomed Inform"},{"key":"10.1053\/j.ajkd.2016.11.016_bib24","doi-asserted-by":"crossref","first-page":"452","DOI":"10.1038\/bmt.2012.244","article-title":"Investigation of the freely available easy-to-use software \u2018EZR\u2019 for medical statistics","volume":"48","author":"Kanda","year":"2013","journal-title":"Bone Marrow Transplant"},{"key":"10.1053\/j.ajkd.2016.11.016_bib25","doi-asserted-by":"crossref","first-page":"634","DOI":"10.1128\/AAC.05609-11","article-title":"Vancomycin AUC24\/MIC ratio in patients with complicated bacteremia and infective endocarditis due to methicillin-resistant Staphylococcus aureus and its association with attributable mortality during hospitalization","volume":"56","author":"Brown","year":"2012","journal-title":"Antimicrob Agents Chemother"},{"key":"10.1053\/j.ajkd.2016.11.016_bib26","doi-asserted-by":"crossref","first-page":"925","DOI":"10.2165\/00003088-200443130-00005","article-title":"Pharmacodynamics of vancomycin and other antimicrobials in patients with Staphylococcus aureus lower respiratory tract infections","volume":"43","author":"Moise-Broder","year":"2004","journal-title":"Clin Pharmacokinet"},{"issue":"3","key":"10.1053\/j.ajkd.2016.11.016_bib27","doi-asserted-by":"crossref","first-page":"307","DOI":"10.1002\/jcph.600","article-title":"Population pharmacokinetics of meropenem during continuous infusion in surgical ICU patients","volume":"56","author":"Kees","year":"2016","journal-title":"J\u00a0Clin Pharmacol"},{"key":"10.1053\/j.ajkd.2016.11.016_bib28","doi-asserted-by":"crossref","first-page":"632","DOI":"10.1097\/FTD.0000000000000065","article-title":"Comparison of equations with estimate renal function to predict serum vancomycin concentration in patients with spinal cord injury\u2013does the use of cystatin C improve accuracy?","volume":"36","author":"DeCarolis","year":"2014","journal-title":"Ther Drug Monit"},{"key":"10.1053\/j.ajkd.2016.11.016_bib29","doi-asserted-by":"crossref","first-page":"48","DOI":"10.3346\/jkms.2013.28.1.48","article-title":"Serum cystatin C is a major predictor of vancomycin clearance in a population pharmacokinetic analysis of patients with normal serum creatinine concentrations","volume":"28","author":"Chung","year":"2013","journal-title":"J\u00a0Korean Med Sci"},{"key":"10.1053\/j.ajkd.2016.11.016_bib30","doi-asserted-by":"crossref","first-page":"326","DOI":"10.1097\/01.ftd.0000211805.89440.3d","article-title":"Serum cystatin C for the prediction of\u00a0glomerular filtration rate with regard to the dose adjustment of amikacin, gentamicin, tobramycin, and vancomycin","volume":"28","author":"Hermida","year":"2006","journal-title":"Ther Drug Monit"},{"key":"10.1053\/j.ajkd.2016.11.016_bib31","doi-asserted-by":"crossref","first-page":"545","DOI":"10.1016\/j.ijantimicag.2010.07.015","article-title":"Clearance of vancomycin during continuous infusion in intensive care unit patients: correlation with measured and estimated creatinine clearance and serum cystatin C","volume":"36","author":"Kees","year":"2010","journal-title":"Int J Antimicrob Agents"},{"key":"10.1053\/j.ajkd.2016.11.016_bib32","doi-asserted-by":"crossref","first-page":"485","DOI":"10.1016\/j.clinbiochem.2007.01.008","article-title":"Serum cystatin C as a better marker of vancomycin clearance than serum creatinine in elderly patients","volume":"40","author":"Okamoto","year":"2007","journal-title":"Clin Biochem"},{"key":"10.1053\/j.ajkd.2016.11.016_bib33","doi-asserted-by":"crossref","first-page":"778","DOI":"10.1128\/AAC.00661-09","article-title":"Population pharmacokinetic analysis of vancomycin using serum cystatin C as a marker of renal function","volume":"54","author":"Tanaka","year":"2010","journal-title":"Antimicrob Agents Chemother"},{"key":"10.1053\/j.ajkd.2016.11.016_bib34","doi-asserted-by":"crossref","first-page":"261","DOI":"10.1097\/FTD.0b013e31803bcfd2","article-title":"Estimation of the initial dose setting of vancomycin therapy with use of cystatin C as\u00a0a new marker of renal function","volume":"29","author":"Tanaka","year":"2007","journal-title":"Ther Drug Monit"},{"key":"10.1053\/j.ajkd.2016.11.016_bib35","doi-asserted-by":"crossref","first-page":"592","DOI":"10.5414\/CPP45592","article-title":"Hoek's formula, a cystatin C-based prediction formula for determining the glomerular filtration rate, is the most effective method for original adjusting the dosage of vancomycin","volume":"45","author":"Tanaka","year":"2007","journal-title":"Int J Clin Pharmacol Ther"},{"key":"10.1053\/j.ajkd.2016.11.016_bib36","doi-asserted-by":"crossref","first-page":"20","DOI":"10.1111\/bcp.12602","article-title":"Cystatin C as a potential biomarker for dosing of renally excreted drugs","volume":"80","author":"Brou","year":"2015","journal-title":"Br J Clin Pharmacol"},{"key":"10.1053\/j.ajkd.2016.11.016_bib37","doi-asserted-by":"crossref","first-page":"441","DOI":"10.1592\/phco.31.5.441","article-title":"Validation of the effectiveness of a vancomycin nomogram in achieving target trough concentrations of 15-20 mg\/L suggested by the vancomycin consensus guidelines","volume":"31","author":"Kullar","year":"2011","journal-title":"Pharmacotherapy"},{"key":"10.1053\/j.ajkd.2016.11.016_bib38","doi-asserted-by":"crossref","first-page":"840","DOI":"10.1097\/CCM.0b013e3181961bff","article-title":"Pharmacokinetic issues for antibiotics in the critically ill patient","volume":"37","author":"Roberts","year":"2009","journal-title":"Crit Care Med"},{"issue":"suppl 1","key":"10.1053\/j.ajkd.2016.11.016_bib39","doi-asserted-by":"crossref","first-page":"S35","DOI":"10.1086\/491712","article-title":"The pharmacokinetic and pharmacodynamic properties of vancomycin","volume":"42","author":"Rybak","year":"2006","journal-title":"Clin Infect Dis"},{"key":"10.1053\/j.ajkd.2016.11.016_bib40","doi-asserted-by":"crossref","first-page":"1863","DOI":"10.1128\/AAC.01149-08","article-title":"Prospectively validated dosing nomograms for maximizing the pharmacodynamics of vancomycin administered by continuous infusion in critically ill patients","volume":"53","author":"Pea","year":"2009","journal-title":"Antimicrob Agents Chemother"}],"container-title":["American Journal of Kidney Diseases"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0272638616307089?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0272638616307089?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,10,3]],"date-time":"2025-10-03T03:01:45Z","timestamp":1759460505000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0272638616307089"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2017,5]]},"references-count":40,"journal-issue":{"issue":"5","published-print":{"date-parts":[[2017,5]]}},"alternative-id":["S0272638616307089"],"URL":"https:\/\/doi.org\/10.1053\/j.ajkd.2016.11.016","relation":{},"ISSN":["0272-6386"],"issn-type":[{"value":"0272-6386","type":"print"}],"subject":[],"published":{"date-parts":[[2017,5]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Cystatin C\u2013Guided Vancomycin Dosing in Critically Ill Patients: A\u00a0Quality Improvement Project","name":"articletitle","label":"Article Title"},{"value":"American Journal of Kidney Diseases","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1053\/j.ajkd.2016.11.016","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2017 by the National Kidney Foundation, Inc.","name":"copyright","label":"Copyright"}]}}